# **Supporting Information**

# Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series

Christine Dahlke\*, Jasmin Heidepriem, Robin Kobbe, René Santer, Till Koch, Anahita Fathi, My L. Ly, Stefan Schmiedel, Peter H. Seeberger, ID-UKE COVID-19 study group, Marylyn M. Addo\*, Felix F. Loeffler\*

### Flow cytometry

Flow cytometry was used to analyze B-cell phenotype of immune cells. Cryopreserved PBMCs were isolated and stained using the following antibodies.

Product	Company	Clone
B-cell panel		
Zombie Aqua live/dead	Biolegend	-
CD19 BUV395	BD	SJ25C1
CD3 APC-Cy7	Biolegend	SK7
CD24 BV605	Biolegend	ML5
CD27 BV711	Biolegend	0323
CD38 BV421	Biolegend	HIT2

#### **Table S1.** Antibodies used for flow cytometry

# Patient Material

Blood from four patients and one healthy control were collected at the University Medical Center Hamburg-Eppendorf. Donors provided written informed consent. The protocol was approved by the Ethics Committee of the Hamburg Medical Association, Germany. Peripheral blood mononuclear cells (PBMCs) were isolated and cryopreserved from EDTA-blood using standard operating procedures via Ficoll density gradient centrifugation. Serum samples were aliquoted and stored at -80°C.

# Peptide microarrays

The whole proteome of SARS-CoV-2 (GenBank ID: MN908947.3) was mapped as overlapping sequences on peptide microarrays. The sequences of ORF1ab polyprotein, spike glycoprotein (S), ORF3a protein, envelope protein (E), membrane glycoprotein (M), ORF6 protein, ORF7a protein, ORF8 protein, nucleocapsid phosphoprotein (N), and ORF10 protein were elongated and linked by neutral GSGSGSG linkers to avoid truncated peptides. The elongated protein sequences were

translated into 4 883 different 15 amino acid peptides printed in duplicate (9 766 peptide spots) with a peptide-peptide overlap of 13 amino acids for high resolution epitope data. Peptide microarrays were obtained from PEPperPRINT GmbH (Heidelberg, Germany).

#### Processing and analysis of peptide microarrays

Before incubation of the serum samples, the arrays were pre-swollen for 15 min with 1.6 mL PBST (0.05 % (v/v) Tween 20 in PBS) at room temperature and orbital shaking at 100 rpm. To avoid nonspecific binding of the serum proteins, the arrays were incubated with blocking buffer (MB-070, Rockland Immunochemicals Inc., Limerick, USA) for 30 min at 100 rpm and room temperature. After short washing with PBST, 1.6 mL of sera, diluted 1:200 in staining buffer (10 % (v/v) blocking buffer in PBST), were incubated overnight at 100 rpm and 4 °C. To remove unbound serum components, the arrays were washed quickly three times with PBST. The human serum antibody classes IgG, IgM and IgA were detected with fluorescently labeled secondary antibodies: 0.5 mg/ml anti-human IgG-Fc fragment cross-adsorbed DyLight 680 conjugated (A80-304D6, Bethyl Laboratories, Montgomery, USA), 1.0 mg/ml anti-human IgM (mu chain) DyLight 549 conjugated (609-142-007, Rockland Immunochemicals Inc., Limerick, USA), 1.0 mg/ml antihuman IgA (alpha chain) antibody DyLight 800 conjugated (609-145-006, Rockland Immunochemicals Inc., Limerick, USA). The HA control peptides on the array were detected with 1.0 mg/ml anti-HA-peptide antibody (RT028, Bio X Cell, New Hampshire, USA) labeled with Lightning-Link Rapid Dylight 680 (327-0010, Innova Biosciences Ltd., Cambridge, United Kingdom). The secondary antibodies were diluted in staining buffer (anti-human IgG 1:1 000, antihuman IgA 1:1 600, anti-human IgM 1:2 000 and anti-HA-peptide 1:2 000) and applied to the microarrays for 30 min at 100 rpm at room temperature in the dark. To remove unbound secondary antibodies, the arrays were washed quickly three times with PBST. Finally, the arrays were dipped in 1 mM Tris HCl pH 7.4 and dried in a jet of air. The arrays were scanned and fluorescence signals were detected at 700 nm and 800 nm using an Odyssey Scanner (LI-COR Biotechnology Inc., Lincoln, Nebraska, USA) and at 532 nm with a Genepix 4000B (Molecular Devices, San José, USA). Analysis of the scans was performed using PepSlide Analyzer software (SICASYS Software GmbH, Heidelberg, Germany).

**Table S2.** Number of reactive SARS-CoV-2 peptides at different time points targeted by IgA and IgG antibodies of patients #1 - #4. Data derived from peptide microarray data, showing hits for ORF1ab polyprotein, spike glycoprotein, and all proteins.

IgA		Number of peptides above threshold (99.9th percentile of healthy control sample*)									
	Patient ID	#1			#2		#3	#	#4		
	Days after onset of symptoms	d6	d10	d22	d3	d15	d24	d12	d4	d11	Control
	ORF1ab polyprotein	3	20	67	10	2	0	18	167	79	5
	Spike glycoprotein	0	1	24	2	1	0	0	21	9	0
	ORF3a protein	0	0	0	0	0	0	4	8	0	0
	Envelope protein	0	0	0	1	1	0	1	0	0	0
tein	Membrane glycoprotein	0	1	4	0	0	0	1	0	0	0
Prot	ORF6 protein	0	0	0	0	0	0	1	1	0	0
_	ORF7a protein	0	0	0	0	0	0	0	4	1	0
	ORF8 protein	0	0	6	0	0	0	0	10	8	0
	Nucleocapsid phosphoprotein	0	1	7	0	1	0	0	3	0	0
	ORF10 protein	0	0	0	0	0	0	0	0	0	0
	Total	3	23	108	13	5	0	25	214	97	5

lgG		Number of peptides above threshold (99.9th percentile of healthy control sample*)									
	Patient ID		#1			#2		#3	#	<b>#4</b>	#5
	Days after onset of symptoms	d6	d10	d22	d3	d15	d24	d12	d4	d11	Control
	ORF1ab polyprotein	5	3	11	7	3	1	1	6	3	2
	Spike glycoprotein	2	4	7	1	0	0	0	3	0	0
	ORF3a protein	0	0	0	0	0	0	1	1	1	2
	Envelope protein	0	0	0	0	0	0	0	0	0	0
ein	Membrane glycoprotein	1	1	4	0	0	0	0	1	1	1
Prot	ORF6 protein	0	0	0	0	0	0	0	0	0	0
_	ORF7a protein	0	0	0	0	0	0	0	0	0	0
	ORF8 protein	0	0	0	0	0	0	0	0	0	0
	Nucleocapsid phosphoprotein	3	7	6	0	0	0	2	0	0	0
	ORF10 protein	0	0	0	0	0	0	0	0	0	0
	Total	11	15	28	8	3	1	4	11	5	5

lgM		Number of peptides above threshold (99.5th percentile of healthy control sample*)									
	Patient ID	#1				#2			#	<b>#4</b>	#5
	Days after onset of symptoms	d6	d10	d22	d3	d15	d24	d12	d4	d11	Control
	ORF1ab polyprotein	2	2	3	21	1	1	20	19	18	23
	Spike glycoprotein	0	0	8	0	0	0	0	0	1	1
	ORF3a protein	0	0	0	0	0	0	1	1	0	1
	Envelope protein	1	1	1	1	0	0	0	0	0	0
tein	Membrane glycoprotein	0	0	0	0	0	0	0	0	0	0
Prot	ORF6 protein	0	0	0	1	0	0	0	0	0	0
	ORF7a protein	0	0	0	0	0	0	0	0	0	0
	ORF8 protein	0	0	0	0	0	0	0	0	0	0
	Nucleocapsid phosphoprotein	0	0	1	0	0	0	0	0	0	0
	ORF10 protein	0	0	0	0	0	0	0	0	0	0
	Total	3	3	13	23	1	1	21	20	19	25

**Table S3.** Positive SARS-CoV-2 peptides in IgG, IgA, and IgM response for the spike glycoprotein, membrane glycoprotein, and nucleocapsid phosphoprotein.

Spike glycoprotein (S)									
lgG		lgA		lgM					
Position	Peptide	Position 45-59 63-91	Peptide SSVLHSTQDLFLPFF TWFHAIHVSGTNGTKBEDNPV	Position 45-59	Peptide SSVLHSTQDLFLPFF				
		425 404	LPFNDGVY						
		125-181	NVVIKVCEFQFCNDPFLGVYYH KNNKSWMESEFRVYSSANNC TFEYVSQPFLMDLEG						
		215-229	DLPQGFSALEPLVDL						
		241-265	LLALHRSYLTPGDSSSGWTAGA AAY	241-265	LLALHRSYLTPGDSSSGWTAGA AAY				
		271-295	QPRTFLLKYNENGTITDAVDCA LDP						
369-383	YNSASFSTFKCYGVS	343-357	NATRFASVYAWNRKR						
		415-429	TGKIADYNYKLPDDF						
		449-463	YNYLYRLFRKSNLKP						
		565-587	FGRDIADTTDAVRDPQTLEILDI						
		605-619	SNQVAVLYQDVNCTE						
637-651	STGSNVFQTRAGCLI	647-665	AGCLIGAEHVNNSYECDIP						
725-739	EILPVSMTKTSVDCT	721-735	SVTTEILPVSMTKTS						
811-831	KPSKRSFIEDLLFNKVTLADA	809-827	PSKPSKRSFIEDLLFNKVT						
927-955	FNSAIGKIQDSLSSTASALGKLQ DVVNQN	835-851	KQYGDCLGDIAARDLIC						
		1087-1111	AHFPREGVFVSNGTHWFVTQ RNFYE						
		1131-1145	GIVNNTVYDPLQPEL	1127-1141	DVVIGIVNNTVYDPL				
1201-1217	QELGKYEQYIKWPWYIW	1193-1215	LNESLIDLQELGKYEQYIKWPW Y	1143-1157	PELDSFKEELDKYFK				
		Memb	rane glycoprotein (M)						
IgG		IgA							
Position	Peptide	Position	Peptide						
1-7	MADSNGT	1-25	MADSNGTITVEELKKLLEQWN LVIG						
203-222	NYKLNTDHSSSSDNIALLVQ								
		Nucleoca	osid phosphoprotein (N)						
lgG		IgA		lgM					
Position	Peptide	Position	Peptide	Position	Peptide				
		96-110	GGDGKMKDLSPRWYF						
		156-170	AIVLQLPQGTTLPKG						
176-206	SRGGSQASSRSSSRSRNSSRNS TPGSSRGTS	182-196	ASSRSSSRSRNSSRN	182-196	ASSRSSSRSRNSSRN				
		236-262	GKGQQQQGQTVTKKSAAEAS KKPRQKR						
		276-298	RRGPEQTQGNFGDQELIRQGT DY						
366-382	TEPKKDKKKKADETQAL	332-346	TYTGAIKLDDKDPNF						
392-406	VTLLPAADLDDFSKQ	380-394	QALPQRQKKQQTVTL						



**Figure S1.** Evolution of reactive SARS-CoV-2 peptides at different time points targeted by IgA (left) and IgG (right) antibodies of patient #4 (moderate symptoms, non-hospitalized).



**Figure S2.** Number of reactive SARS-CoV-2 peptides at different time points targeted by IgA and IgG antibodies of patient #4. Data derived from peptide microarrays, showing hits for all proteins, ORF1ab polyprotein, and spike glycoprotein.